期刊文献+

雷公藤甲素脂质体粉雾剂的处方工艺筛选与评价 被引量:1

Screening and Evaluation of Formulation Technology of Friptolide Liposome Powder Spray
下载PDF
导出
摘要 为降低雷公藤甲素的毒副作用,制备雷公藤甲素脂质体粉雾剂(TP-LD),并进行初步评价。方法采用乙醇注入法和冷冻干燥法制备雷公藤甲素脂质体粉雾剂,并对其进行处方工艺的研究和制剂学评价。结果 雷公藤甲素脂质体包封率为(74.6±1.7)%,粒径大小为(113.03±2.4) nm;Zeta电位为(-43.60±1.2) mv;冻干复溶后TP-LD的粒径大小为(1.17±0.047)μm,流动性与亲水性均较好,满足粉雾剂给药的基本要求。结论 成功制备雷公藤甲素脂质体粉雾剂,工艺简单可行、质量稳定。 Triptolide liposome powder spray(TP-LD) was prepared and evaluated it in order to reduce the toxic and side effects of triptolide.Triptolide liposome powder was prepared by ethanol injection method and freeze-drying method, and its formulation technology was studied and evaluated.Results showed that the entrapment efficiency of triptolide liposomes was(74.6±1.7)%,the particle size was(113.03± 2.4) nm, and the zeta potential was(-43.60±1.2) MV. After freeze-drying, the particle size of the powder spray was(1.17±0.047)μm and the fluidity and hydrophilicity were good, which met the basic requirements of powder spray administration. Triptolide liposome powder spray was successfully prepared with simple and feasible process and stable quality.
作者 史亚玲 李淼兰 谢立颖 姚志喻 陈卉 SHI Ya-ling;LI Miao-lan;XIE Li-ying;YAO Zhi-yu;CHEN Hui(School of Pharmacy,Guilin Medical University,Guangxi Guilin 541199,China)
出处 《广州化工》 CAS 2022年第19期82-85,共4页 GuangZhou Chemical Industry
基金 广西大学生创新创业项目(No:202010601020)。
关键词 雷公藤甲素 粉雾剂 脂质体 工艺筛选 体外释放 triptolide powder spray liposomes process screening in vitro release
  • 相关文献

参考文献7

二级参考文献81

  • 1陈桂良,侯惠民.吸入用气雾剂雾粒测定方法的评价[J].中国医药工业杂志,2007,38(3):194-199. 被引量:24
  • 2Kwok PCL, Chan HK. Delivery of inhalation drugs to children for asthma and other respiratory diseases[J ]. A dv Drug Delivery Rev, 2014, 73: 83-88.
  • 3Frmnpton MW, Stewart JC, Oberdorster G. Inhalation of ultrafine particles alters blood leukocyte expression of adhesion molecules in humans [J]. Environ Health Perspect, 2006, 114 (I): 51-58.
  • 4Newhouse M, Hirst P, Duddu S, et all. Inhalation of a dry powder tobramycin pulmosphere formulation in healthy volunteers [J]. Chest, 2003, 124(1): 360-366.
  • 5Asmus M. In vitro performance of two common valved holding chambers with a chlorofluorocarbon-free beclomethasone metered-dose inhaler [J]. Pharmootherapy, 2003, 23(12): 1538-1544.
  • 6Abbas A, Srour M, Tang P, et o1. Sonocrystallisation of sodium chloride particles for inhalation [J]. Chem Eng Sci, 2007, 62 (9): 2445-2453.
  • 7Chiou H, Li L, Hu T, et al. Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation [J]. Int JPharm, 2007, 331(1): 93-98.
  • 8Atkins P J. Dry powder inhalers: an overview [J]]. Respir Care, 2005, 50(10): 1304-1312.
  • 9Yang W, Peters JI, O. Williams R. Inhaled nanoparticles-A carrent review[J], lnt JPharm, 2008, 356(1/2): 239-247.
  • 10Zhang J, Wu L, Chan HK, et al. Formation, characterization, and fate of in haled drug nanoparticles [J]. Adv Delivery Rev, 2011, 63: 441-455.

共引文献64

同被引文献7

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部